FDA Grants RMAT Designation to Grace Science's GS-100 Gene Therapy for NGLY1 Deficiency
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GS-100, a gene therapy developed by Grace Science, LLC, for treating NGLY1 Deficiency. This ultra-rare genetic disease affects children and currently has no approved therapies. GS-100 is an investigational adeno-associated viral vector therapy designed to replace the deficient NGLY1 protein. The RMAT designation is based on promising early clinical evidence showing improvements in motor function and cognitive skills in patients treated with GS-100. This designation aims to expedite the development and review process, potentially leading to accelerated approval. 
